The wonderful thing about Pemetrexed is that it absolutely kills cancer cells. The awful thing about Pemetrexed is that it absolutely kills healthy cells. Every chemo treatment that I have leaves m…

Health update: Pain and fatigue 5 out of 10 at start of day, increased post pemetrexed. We were at our 9 week for the B12 injection. No clue how bad I'd feel without it! 😅 (laughing emoji with a drop of forehead sweat) I've learned that the Keytruda and carboplatin were nice diluters for the toxicity of the pemetrexed. Pemetrexed wipes me out fast and gifts full body pain when infused without its friends.

El tratamiento con osimertinib más una combinación de quimioterapia con platino y pemetrexed resultó en...

EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab and platinum-pemetrexed ...

A clinical presentation of unilateral lower extremity edema, pain, and erythema is commonly diagnosed and treated as cellulitis in the inpatient setting. However, for patients with cancer, the differe...

Introduction: Chemo-immunotherapy has reshaped the treatment of metastatic non-small cell lung cancer (NSCLC), yet data on varicella-zoster virus (VZV) reactivation under these regimens are limited. Major immunotherapy trials do not specifically describe herpes zoster events in patients receiving combined chemotherapy and immune checkpoint inhibitors. Methods: We describe a case of metastatic lung adenocarcinoma (ADC) treated with first‑line Pemetrexed-Carboplatin-Pembrolizumab plus Denosumab in which herpes zoster occurred during treatment, detailing clinical course, management, and outcomes. Results: We report a 64-year-old former smoker with metastatic lung ADC involving lymph nodes and bone, Programmed Cell Death Protein Ligand (PD-L1) expression 0%, and no actionable oncogenic alterations. He was treated with first-line Pemetrexed-Carboplatin-Pembrolizumab plus Denosumab. Treatment was well tolerated, and post-cycle 4 imaging showed stable disease according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. Approximately four months after initiation of chemo-immunotherapy, he developed a painful, unilateral, dermatomal vesicular eruption over the right lower thorax, clinically consistent with herpes zoster. The diagnosis of herpes zoster was clinical rather than microbiological. Systemic anticancer therapy was temporarily suspended. The patient received oral Acyclovir, step II analgesics, and local wound care for 14 days. Complete resolution of skin lesions and pain occurred within three weeks, without zoster-related complications. Maintenance Pemetrexed-Pembrolizumab-Denosumab was then resumed, with sustained tumor control and no recurrence of herpes zoster during follow-up. Conclusion: This case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.

Background Pemetrexed is a key treatment for non-small-cell lung cancer (NSCLC), and its usage is increasing. However, owing to treatment-related fatality in a patient with severe renal impairment…

Stay up-to-date on new USP product releases, training courses and other announcements.

Fontes et al. report a case study of a person with recurrent glioblastoma for whom patient-derived zebrafish xenografts (zAvatars) were used to test 13 off-label therapies with radiotherapy. zAvatars identified pemetrexed and doxorubicin as effective, guiding treatment that stabilized the patient.

Pembrolizumab in Pleural Mesothelioma | Image Credit: © lertsakwiman– stock.adobe.comHealth Canada has approved the anti-PD-1 pembrolizumab (Keytruda) plus pemetrexed and platinum-based chemotherapy for the first-line treatment of adults with unresectable advanced or metastatic malignant pleural mesothelioma.The regulatory decision was based on data from the pivotal phase 3 IND.227/KEYNOTE-483 trial (NCT02784171), which showed a statistically significant improvement in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) in patients who were randomly assigned to receive pembrolizumab plus chemotherapy vs those treated with chemotherapy alone.“This approval marks the first combination treatment of and chemotherapy in Canada for patients with

Until 2024, the preferred first-line treatment for epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) advanced non-small cell lung cancer (NSCLC) was osimertinib, a third-gene...

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Ex20ins) mutations. The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).